News Detail

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Benzinga · 08/04 11:46

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Leerink Partners analyst Jonathan Chang upgraded Replimune Group Inc (NASDAQ:REPL) from Market Perform to Outperform and raised the price target from $11 to $17. Replimune Group closed at $11.91 on Monday. See how other analysts view this stock.
Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) from Peer Perform to Outperform and announced a $605 price target. Madrigal Pharmaceuticals shares closed at $482.00 on Monday. See how other analysts view this stock.
UBS analyst Rodrigo Alcantara upgraded BBB Foods Inc (NYSE:TBBB) from Neutral to Buy and raised the price target from $43 to $51. BBB Foods closed at $42.85 on Monday. See how other analysts view this stock.
Deutsche Bank analyst Brad Zelnick upgraded Palantir Technologies Inc (NASDAQ:PLTR) from Hold to Buy and maintained the price target of $200. Palantir shares closed at $125.65 on Monday. See how other analysts view this stock.
B of A Securities analyst Robert Ford upgraded Fomento Economico (NYSE:FMX) from Neutral to Buy and raised the price target from $125 to $150. Fomento Economico shares closed at $125.75 on Monday. See how other analysts view this stock.

Considering buying PLTR stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.